A French early-access program analyzing 3,709 routine patients reported that 177Lu-PSMA-617 delivered efficacy and safety outcomes closely aligned with the VISION trial. The program found a median progression-free survival of 7.6 months and disease control in 82% of patients, supporting the translational relevance of trial results to real-world metastatic castration-resistant prostate cancer. For treatment planning, the dataset helps benchmark expected outcomes in broader clinical settings, where patient selection can differ from controlled trials and where operational experience with radioligand therapy matters for scaling care.